2245084-40-4Relevant academic research and scientific papers
REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF
-
, (2021/08/27)
The present invention relates to a regulator of nitrogen-containing heteroaromatic derivatives, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protein tyrosine phosphatase-2C (SHP2) inhibitor in the treatment of diseases or conditions such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colorectal cancer, wherein the definition of each substituent in the general formula (I) is the same as that in the description.
PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF
-
, (2021/10/07)
The present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative, a preparation method therefor, and the medical uses thereof. Particularly, the present invention relates to a pyrimidine and a five-membered nitrogen hetero
Salt of nitrogen-containing heteroaromatic derivative and crystal form thereof
-
Paragraph 1220; 1231-1234, (2021/10/13)
The invention relates to a salt of a nitrogen-containing heteroaromatic derivative and a crystal form thereof. The invention specifically relates to a salt with a general formula (I) and a crystal form thereof. A preparation method and a pharmaceutical composition containing the salt of the derivative and a crystal form thereof, as a protein tyrosine phosphatase - 2C (SHP2) inhibitor, and application thereof to treatment of diseases or diseases such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colon cancer.
Compound serving as SHP2 inhibitor and application thereof
-
Paragraph 0238; 0249-0251, (2021/05/12)
The invention belongs to the field of medical chemistry, relates to a compound serving as an SHP2 inhibitor and an application of the compound, and particularly provides a compound shown in a formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug of the compound, processes for the preparation, pharmaceutical compositions containing these compounds and the use of these compounds or compositions for the treatment of SHP2 mediated diseases.
SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF
-
Page/Page column 46; 47, (2021/11/06)
Provided herein are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.
SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF
-
Paragraph 0166, (2020/10/20)
Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.
IMIDAZOPYRIMIDINE DERIVATIVES
-
Paragraph 0853; 0855, (2020/04/29)
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.
PROTEIN TYROSINE PHOSPHATASE INHIBITORS
-
, (2020/05/21)
Compounds of Formula la or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases in the view of their ability to inhibit SHP2. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
PROTEIN TYROSINE PHOSPHATASE INHIBITORS
-
, (2020/10/20)
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
-
Page/Page column 86-87, (2020/05/12)
Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.
